v3.25.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development $ 7,627 $ 4,340
General and administrative 3,309 3,634
Loss from operations (10,936) (7,974)
Other income (expense), net:    
Interest expense (161) (368)
Interest income and other income (expense), net 237 438
Total other income (expense), net 76 70
Provision for income taxes 0 0
Net loss $ (10,860) $ (7,904)
Net loss per share of common stock, RSUs and pre-funded warrants, basic $ (3.16) $ (4.62)
Net loss per share of common stock, RSUs and pre-funded warrants, diluted $ (3.16) $ (4.62)
Weighted-average shares of common stock, RSUs and pre-funded warrants outstanding, basic [1] 3,437,671 1,710,323
Weighted-average shares of common stock, RSUs and pre-funded warrants outstanding, diluted [1] 3,437,671 1,710,323
[1] Results, including shares of common stock, have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.